Major depressive disorder (MDD), a common chronic mental disorder, is mainly manifested by changes in emotion, cognition, behavior, sleep and appetite, and it can result in impaired overall social function. MDD is among the leading causes of suicide and disability. The prevalence of MDD is high, with nearly one in four women or six men suffering from MDD ([@B38]). In addition, relapse is common in MDD. Approximately 60% of first-onset depressed patients will suffer from a second episode ([@B50]). In sharp contrast to high prevalence rate, the recognition rate of MDD is quite low. Among the existing MDD patients in China, only a few have received relevant treatment, and a majority of patients can't be diagnosed and treated effectively and timely. The pathogenesis of MDD is very complex, and it has not been uniformly determined. Fibroblast growth factors (FGFs) belong to a large family of growth factors that are involved in brain development during early periods as well as maintenance and repair throughout adulthood ([@B75]). Many studies show that some members of FGF system are correlated with depression. We used "fibroblast growth factor" or "FGF" and mood related words (e.g., "major depressive disorder," "depression," "mood disorder," or "stress") to perform electronic searches of the English-language literatures in PubMed. References of the retrieved articles were manually screened to identify other relevant publications. Here, we mainly concentrated on the reported depression-related FGF system members, including FGFR1, FGF2, FGF9, FGF21, and FGF22.

Fibroblast Growth Factors and Fibroblast Growth Factor Receptors
================================================================

The FGF system is composed of twenty-two ligands and five receptors at present in humans and is distributed throughout the central nervous system ([@B78]). FGFs play a key role in the function, development and metabolism of neuron. During development, FGFs control the growth and morphology of several brain structures, and in the later stages of life, they continue to regulate neurogenesis, axon growth, neuroprotection, and nervous tissue maintenance and repair ([@B74]). Although structurally related, FGFs show different action patterns, secretory mechanisms and biological effects. Thereby they are divided into several subfamilies ([Table 1](#T1){ref-type="table"}), and each subfamily has its genetic and functional similarity ([@B28]; [@B22]; [@B5]; [@B26]). Unlike other subfamilies, FGF homologous factor (FHF) subfamily cannot activate FGF receptors ([@B56]).

###### 

FGF subfamilies and their members ([@B28]; [@B22]; [@B5]; [@B26]).

  FGF subfamily                           Members                                                  Binding receptor                                                                                                                                                                                                 Potential effects                                                                                                                                                                                                                    Secretory patterns
  --------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------
  FGF1 subfamily                          FGF1                                                     all FGF receptors                                                                                                                                                                                                FGF1 subfamily members have some therapeutic potential for cardiovascular disorders, mood disorders, cancers, and are widely used for wound healing.                                                                                 Paracrine Subfamilies (Cofactor: heparin)
                                          FGF2                                                     FGFR1c,3c,2c,1b,4                                                                                                                                                                                                                                                                                                                                                                                                                                     
  FGF4 subfamily                          FGF4, FGF5, FGF6                                         FGFR1c,2c,3c,4                                                                                                                                                                                                   FGF4 subfamily members have wide-ranging functions in development, including cardiac valve leaflet formation and limb development.                                                                                                   
  FGF7 subfamily                          FGF3, FGF7, FGF10, FGF22                                 FGFR2b,1b                                                                                                                                                                                                        FGF7 and FGF10, also known as keratinocyte growth factors, act as presynaptic organizers with roles in vesicle clustering and neurite branching. Recombinant FGF7 is widely used for wound healing.                                  
  FGF8 subfamily                          FGF8, FGF17, FGF18                                       FGFR3c,4,2c,1c,3b                                                                                                                                                                                                FGF8 is involved in brain, limb, ear and eye development.                                                                                                                                                                            
  FGF9 subfamily                          FGF9, FGF16, FGF20                                       FGFR3c,2c,1c,3b,4                                                                                                                                                                                                FGF20 is a neurotrophic factor for rat midbrain dopaminergic neurons, and may show promise in stem cell biology.                                                                                                                     
  FGF19 subfamily                         FGF19, FGF21, FGF23                                      FGFR1c,2c,3c,4 (Weak activity)                                                                                                                                                                                   Since Klotho expression is tissue-specific, the functions of FGF19 subfamily members are mainly related to human metabolic processes, such as regulating the balance of bile acid, cholesterol, glucose, vitamin D, and phosphate.   Endocrine Subfamily (Cofactor: Klotho)
  FGF homologous factor (FHF) subfamily   FGF11 (FHF3), FGF12 (FHF1), FGF13 (FHF2), FGF14 (FHF4)   FHFs have high sequence identity with other FGF family members, but do not activate FGFR. FHFs bind to intracellular domains of voltage-gated sodium channels (VGSCs) and to a neuronal MAPK scaffold protein.   FHF deficits induce neurological syndromes, such as impaired central nervous system function.                                                                                                                                        /

FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; FHF, FGF homologous factor; MAPK, mitogen-activated protein kinase; VGSCs, voltage-gated sodium channels

.

Fibroblast growth factor receptor (FGFR), a member of the receptor tyrosine kinase family, includes five kinds of receptors, among which FGFR1∼FGFR4 have receptor activity while FGFR5 doesn't due to the absence of intracellular part ([@B91]; [@B29]). Each receptor has a unique affinity for FGFs, and this uniqueness depends on the differential splicing of the third extracellular immunoglobulin-like domain (Ig-III) of the receptor variant ([@B84]).

Interactions of FGFs with their receptors are modulated by cofactors such as heparan sulfate (HS) and Klotho ([@B57]; [@B26]). After FGFs bind to FGFRs, four key signaling pathways, including RAS-RAF-MAPK, PI3K-AKT, STAT, and PLCγ, are activated to influence gene transcription ([@B29]; [@B82]).

FGF Receptors and Depression
============================

FGFR1
-----

Fibroblast growth factor receptor 1 (FGFR1) is widely distributed throughout the nervous system, contributing to hippocampal nerve growth and long-term potentiation ([@B92]; [@B74]). The expression of FGFR1 is high in CA2 and CA3 regions of hippocampus, but low in cortex. One study shows that the wide expression of FGFR1 in embryonic neural progenitor cells plays a role in the formation of the cortical plate and the structure of gyrus and sulcus ([@B64]).

Turner C.A. et al. found that the mRNA expression of FGFR1 was down-regulated in the hippocampus of acute social defeat rats ([@B79]). FGF2 microinjection (200 ng) into the lateral ventricle of rats, which exerts antidepressant-like effects, up-regulates the FGFR1 mRNA in the dentate gyrus ([@B80]). Later, Aurbach E.L. et al. found that slow administration of exogenous FGF9 increased anxiety and depression-like behaviors, and decreased the expression of FGFR1 in the dentate gyrus ([@B2]). These changes in FGFR1 caused by the administration of exogenous FGF2/9 may result from an increase in FGF2/9 in animals or changes in depression status. These findings provide evidence for the potential therapeutic value of FGFR1 in depression.

Although an early microassay study found that the FGFR1 expression did not change in the dorsolateral prefrontal lobe and anterior cingulate gyrus of depressed subjects, a subsequent study found that FGFR1 mRNA was increased in hippocampal CA1, CA4 and dentate nuclei zone of non-psychotic depressed patients compared with healthy controls ([@B15]; [@B21]). Also, a significant increase in FGFR1 gene expression was found in the prefrontal cortex of postmortem depressed patients ([@B76]; [@B23]). The difference in these results may be due to the factors such as sample pH, postmortem interval. Variation in anatomical distribution of FGFR1 and differences in sample size and detection methods may also affect the results.

Furthermore, FGFR1 can interact with other type of receptors to play a role in depression. FGFR1--5-HT1A (5-hydroxytryptamine receptor 1A) heteroreceptor complexes were first observed in 2012, and combined FGF2 and 5-HT1A agonist treatment increased the formation of the complexes and enhanced the synergistic receptor-receptor interactions, which was associated with the development of antidepressant effects ([@B8]; [@B9]). The results of these studies may combine the serotonin hypothesis and the neurotrophic factor hypothesis of depression together.

FGFR2 and FGFR3
---------------

Fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) are weakly expressed in astrocytes of the hippocampus. The expression level of FGFR2 increases with age in the adult stage, while the expression level of FGFR3 remains relatively unchanged in the early development of the adult stage ([@B4]). FGFR2 is mainly expressed in diencephalon, telencephalon and mesencephalon, and plays an important role in neurogenesis, neuroprotection, nerve repair and hippocampal learning ([@B1]; [@B83]; [@B67]), while FGFR3 is mainly expressed in diencephalic glial cells, and plays a role in the development of the caudal telencephalon ([@B18]; [@B49]).

No change in the expression of FGFR2, FGFR3, and FGFR4 was found in the prefrontal cortex of postmortem depressed patients ([@B23]). However, another study found decreased expression of FGFR2 and FGFR3 in the dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate cortex (AnCg) after autopsy on patients with depression ([@B15]). Decreased expression of FGFR2 and FGFR3 was also found in the hippocampus of postmortem depressed patients ([@B2]).

FGFs and Depression
===================

Currently, among the twenty-two identified FGFs, FGF2, FGF9, FGF21, and FGF22 have been found to be associated with depression.

FGF2
----

FGF2, widely expressed throughout the central nervous system, is one of the main neurotrophic factors. FGF2 can regulate hippocampal neurogenesis, synaptic formation and growth, and thereby affects learning, memory, long-term potentiation and response to injury ([@B17]; [@B19]; [@B60]). FGF2 is mainly expressed in neurons and glial cells during puberty and adulthood, and the hippocampus expresses the highest level of FGF2 and its receptors in the brain ([@B18]).

Several experiments demonstrated that the mRNA expression of FGF2 was down-regulated in acute social defeat rats and post-stroke depressed rats ([@B79]; [@B32]). Interestingly, FGF2 levels were up-regulated after antidepressant administration. Maragnoli et al. found that FGF2 mRNA levels in the prefrontal cortex of rats were up-regulated after short-term or long-term combination of fluoxetine and olanzapine ([@B47]). Similarly, after continuous injection of desipramine or fluoxetine on adult rats for 2 weeks, immunoreactivity of FGF2 was increased in neurons of the cerebral cortex and in astrocytes of the hippocampus ([@B3]). One of the underlying mechanisms that how antidepressants up-regulate the levels of FGF2 involves extracellular signal-regulated kinase (ERK)-dependent early growth response 1 (EGR1) signaling pathway in astrocytes. Amitriptyline may activate FGFR and epidermal growth factor receptor (EGFR), which induces the phosphorylation of ERK1/2. Then it increases the expression of EGR1, which in turn, increases FGF2 expression ([@B34]). A number of animal studies have placed their focus on the effects of FGF2 administration. FGF2 microinjection into the lateral ventricle of depressed rats was reported to have antidepressant effects ([@B80]). Moreover, FGF2 treatment could diminish neuronal death in olfactory bulbectomy (OBX) rats, improve OBX induced reduction in hippocampal neurogenesis and reverse OBX induced depression-like behavior ([@B30]). Furthermore, the researchers found that FGF2, rather than amitriptyline, could reverse the behavior alterations in FGF2 knockout mice, indicating FGF2 as a mediator in the antidepressant effects of amitriptyline. Similarly, slow infusion of FGF2 showed antidepressant effects in chronic unpredictable stress (CUS) rats, and the treatment of antidepressants failed to improve depression-like behaviors after the administration of FGFR inhibitors ([@B13]). Though the pathogenesis of depression and how FGFs exert antidepressant effects are unclear, researchers still get some clues from experiments. In chronic unpredictable mild stress (CUMS) mice, FGF2 increased the phosphorylation of ERK and AKT via binding to FGFR1, which up-regulated the expression of Bcl-2, leading to decreased caspase-3 levels. These changes mediated neuroprotective effects and in turn exerted antidepressant effects ([@B85]). By activating ERK/MAPK pathway, FGF2 could also increase the expression of glucocorticoid receptor and might reduce the likelihood of depression ([@B54]). FGF2-ERK signaling pathway was also reported to be involved in the neuroinflammation induced model of depression. In this model, exogenous FGF2 alleviated inflammation-induced impairment in hippocampal neurogenesis by phosphorylating ERK1/2, and reversed depressive-like behavior ([@B73]). Meanwhile, exogenous FGF2 could modulate depressive-like behavior by affecting the levels of pro-inflammatory cytokines (including interlukin-1β, interlukin-6, and tumor necrosis factor-α), anti-inflammatory cytokine (interlukin-10) and CX3CL1 ([@B72]). In brief, the antidepressant effects of FGF2 may be mediated by several signaling pathways and then achieved by neuronal remodeling (including neurogenesis, alterations of synaptic connections and plasticity) and regulation of monoamine neurotransmitter system.

Postmortem studies concerning FGF2 levels in depressive patients were inconsistent. Evans et al. found that the levels of FGF2 in the DLPFC and the AnCg of postmortem depressed patients were significantly lower than those of healthy controls ([@B15]). Gaughran F. et al. observed decreased FGF2 mRNA in the hippocampal CA4 region of postmortem non-psychotic major depressive patients ([@B21]). However, no change in FGF2 gene expression was found in the prefrontal cortex of postmortem depressive patients ([@B23]). Further studies are needed to discover the changes of FGF2 in different brain regions.

There were discrepant results of clinical studies on the relationship between FGF2 and depression. In an early report, no significant difference in plasma FGF2 levels was found between depressive patients and healthy controls ([@B69]). But in this study, patients with MDD were under remission by being treated with antidepressants or mood stabilizers. In another study, decreased serum FGF2 levels were found in depressive patients, and serum FGF2 levels decreased significantly but marginally after 8 weeks of treatment ([@B24]). In contrast, Kahl et al. found that serum FGF2 concentrations were increased in depressed patients with borderline personality disorder ([@B33]). A similar result was found that the FGF2 levels in the peripheral blood of MDD patients with childhood trauma exposure were significantly higher than those of healthy controls ([@B45]). In a latest meta-analysis, peripheral FGF2 levels of depressive patients were significantly higher than those of healthy controls, while no significant difference of FGF2 levels in the central nervous system was found ([@B88]). One of the reasons for the inconsistent in these results is that some depressed patients had been treated when they were enrolled in studies, while other patients were drug free. Another reason is that some patients had comorbidities or special personal histories other than MDD. Different observation time or different ages may also affect the results.

FGF9
----

FGF9, mainly expressed by neurons in the cortex, hippocampus, thalamus, cerebellum and spinal cord, can promote cell survival and inhibit the differentiation of astrocytes ([@B68]; [@B51]; [@B77]; [@B20]; [@B35]; [@B25]; [@B42]; [@B46]). FGF9 not only activates IIIc splice variant of FGFR3, but also activates IIIb splice variant of FGFR3. This binding specificity makes FGF9 relatively special to other subfamily members ([@B58]; [@B62]).

The mRNA expression of FGF9 in the CA1, CA2, CA3 and dentate gyrus of hippocampus was up-regulated in social defeat stress rats ([@B2]). Further experiments found that administrating exogenous FGF9 increased anxiety- and depression-like behaviors, while knocking down endogenous FGF9 expression in the dentate gyrus by lentiviral vector showed decreased anxiety-like behavior in rats ([@B2]). It is well to be reminded that, FGF2 and FGF9 were found to have the opposite effect through chronic administration of FGFs, that is, FGF2 reduced anxiety- and depression-like behaviors, while FGF9 increased anxiety- and depression-like behaviors ([@B80]; [@B59]). These animal studies indicate that FGF9 has an anxiogenic and prodepressant role in the rodent brain. The balance between FGF factors may be crucial to emotional regulation.

Several human studies provide evidence that FGF9 expression was increased in certain brain areas of depressed patients, such as hippocampus, frontal cortex and locus coeruleus ([@B15]; [@B6]; [@B2]). Another study found no change in the expression of FGF9 gene in the prefrontal cortex of postmortem depressive patients ([@B23]). These results suggest that high levels of FGF9 in the brain may exert an important role in the development of mood disorders.

FGF21
-----

FGF21, an important endogenous regulator of glucose and lipid metabolism, has been proposed as a therapeutic target for diabetes and obesity ([@B27]). It also has a strong neuroprotective effect and acts as a mediator of some mood stabilizers ([@B41]). Liver is the main organ that produces FGF21 ([@B39]). Peripheral FGF21 could reach the brain and play a beneficial role in central nervous system ([@B63]). FGF21 can also be detected in human cerebrospinal fluid ([@B70], [@B71]). FGF21 contains 181 amino acid residues and has a molecular weight of about 20 kDa, which is derived from the mature protein of 209 amino acid residues encoded by the FGF21 gene on chromosome 19 ([@B53]).

In a recent study, the FGF21 levels in cerebrospinal fluid were found negatively related to the score of Beck Depression Inventory (BDI) in male subjects. The lower the FGF21 levels were, the more severe the depression was. However, no significant correlation was found in female subjects ([@B44]). The gender difference of the results may be related to estrogen or oxytocin.

FGF22
-----

As a member of FGF family, FGF22 has been found to be significantly associated with the occurrence of epilepsy, cancer, depression and other diseases as well as embryonic brain development ([@B31]; [@B66]; [@B40]; [@B48]). An animal experiment confirmed that FGF22 was involved in the formation of excitatory synapses in hippocampal neurons ([@B87]). FGF22 is mainly expressed in the brain and skin, and its receptor is FGFR2 ([@B52]; [@B15]; [@B5]).

FGF22 knockout mice models display depression-like behaviors (including despair and anhedonia) in forced swim test, tail suspension test and sucrose preference test ([@B87]). The loss of excitatory synapses in the hippocampus induced by the absence of FGF22 and FGFR2 interaction may partly explain the depressive behavior of FGF22 knockout mice.

In a controlled study of 90 first-onset depressive patients and 90 healthy volunteers, decreased serum FGF22 levels were found in depressive patients, and these levels were negatively correlated with the patients' scores of Hamilton Depression Scale. After treatment, FGF22 levels increased along with the relief of depressive symptoms ([@B90]).

Other FGFs
----------

Evans et al. performed autopsies on depressive patients, and found decreased expression of FGF1 in the DLPFC and AnCg, and increased expression of FGF12 in the AnCg ([@B15]). Major information of postmortem studies and clinical researches included in this review is listed in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

###### 

Postmortem studies concerning the correlation between FGFs and depression.

  Study    Samples             Comparison   Numbers   FGF     Main results
  -------- ------------------- ------------ --------- ------- ----------------------------------------------------------------------------------------------------------------
  [@B15]   DLPFC, AnCg         MDD          4         FGF2    FGF2 levels were lower in the AnCg of MDD patients.
                               HC           6         FGF9    FGF9 expression in the DLPFC was increased in MDD patients.
                                                      FGF1    FGF1 levels were decreased in the DLPFC and AnCg of depressive patients.
                                                      FGF12   Increased FGF12 was observed in the AnCg of depressive patients.
  [@B21]   Hippocampus         MDD          9         FGF2    Decreased FGF2 mRNA was found in the hippocampal CA4 region.
                               HC           12                
  [@B23]   Prefrontal cortex   MDD          16        FGF2    No change in FGF2 gene expression was found in the prefrontal cortex of postmortem depressive patients.
                               HC           16                
  [@B6]    locus coeruleus     MDD          12        FGF9    FGF9 expression was increased in depressed patients.
                               HC           8                 
  [@B23]   Prefrontal cortex   MDD          16        FGF9    No change was found in the expression of FGF9 gene in the prefrontal cortex of postmortem depressive patients.
                               HC           16                
  [@B2]    Hippocampus         MDD          36        FGF9    FGF9 expression was increased in depressed patients.
                               HC           56                

AnCg, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; FGF, fibroblast growth factor; HC, healthy control; MDD, major depressive disorder

.

###### 

Main information of clinical researches studying the correlation between FGFs and depression.

  Study    Samples                                                                                                                                            Depression scale used                                                                                               Comorbidity with anxiety                                       Main results                                                                                                                                                                                                               Limitations
  -------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  [@B69]   16 patients in remission from major depressive disorders, 16 healthy controls                                                                      DSM-IV                                                                                                              Not examined                                                   No significant difference in plasma FGF2 levels was found between the MDD patients and the matched control subjects.                                                                                                       Limited sample size; Various medications
  [@B24]   28 pre- and post-treatment MDD patients (10 first episode and 18 recurrent episode), 30 healthy controls                                           DSM-IV, 24-item Hamilton Depression Rating Scale (HDRS-24)                                                          Not examined                                                   Serum FGF2 levels in MDD patients were significantly lower than those in healthy controls (*p* = 0.005), and the serum FGF2 levels decreased significantly but marginally following treatment for 8 weeks (*p* = 0.005).   Limited sample size; Different types of antidepressants
  [@B33]   12 medication-free female patients with a major depressive episode in the context of borderline personality disorder (MDD/BPD), 12 healthy women   DSM-IV, German version of the Symptom Checklist (SCL-90-R), German version of the Beck Depression Inventory (BDI)   Not examined                                                   Increased concentrations of FGF2 were found in MDD/BPD patients compared to the healthy group.                                                                                                                             Limited sample size; No comparative group with current MDD and without BPD
  [@B45]   22 MDD patients with childhood trauma exposure (CTE), 21 MDD patients without CTE, and 22 healthy controls without CTE                             DSM-IV, Zung's Self-rating Depression Scale (SDS), 24-item Hamilton Depression Scale (HAMD)                         Not examined                                                   FGF2 was overexpressed in MDD patients with CTE only but not as much expressed in MDD patients without CTE.                                                                                                                Limited sample size; Biases caused by using questionnaires to assess histories of childhood trauma; Absence of a control group with CTE alone
  [@B90]   90 depressive patients (first episode and without drug treatment), 90 controls                                                                     Chinese classification of mental disorders- third Edition (CCMD-3), HDRS-24                                         Not examined                                                   The patients presented significantly lower serum FGF22 levels, and the levels increased after 8 weeks of treatment.                                                                                                        The loose inclusion criteria (HDRS-24 = 8); No correlation analysis between FGF 22 levels and HDRS scores
  [@B44]   67 volunteers                                                                                                                                      Beck Depression Inventory (BDI), Self-Rating Anxiety Scale (SAS)                                                    No correlation was found between FGF21 levels and SAS scores   A significant association was found between CSF FGF21 levels and BDI scores in male subjects, but not in female subjects.                                                                                                  No control group

BDI, Beck Depression Inventory; BPD, borderline personality disorder; CCMD-3, Chinese Classification of Mental Disorders, Third Edition; CSF, Cerebrospinal fluid; CTE, childhood trauma exposure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; FGF, fibroblast growth factor; HAMD, 24-item Hamilton Depression Scale; HDRS-24, 24-item Hamilton Depression Rating Scale; MDD, major depressive disorder; SAS, Self-Rating Anxiety Scale; SCL-90-R, Symptom Checklist-90-Revised; SDS, Self-rating depression scale

.

Studies on Genetic Variation in FGF Genes
-----------------------------------------

Many efforts have been made at the genetic level to explore the relations between FGFs and depression. Genetic variation of FGF2 can influence the therapeutic effect of antidepressant drugs. For example, several single-nucleotide polymorphisms (SNPs) in FGF2 gene were found to be associated with altered responsiveness to antidepressant treatment in individuals with MDD ([@B36], [@B37]). On the contrary, no SNPs of FGFR2 gene was associated with depression ([@B86]). At the transcriptional level, the enrichment of FGF pathways is found both in depressed patients and rat models by gene expression analysis ([@B11]).

Role of FGFs in Depression
--------------------------

Fibroblast growth factor signaling has functional effects through different mechanisms. FGF2 increases the number or the survival of neurons in the hippocampus ([@B59]; [@B81]), and controls the development and size of the hippocampus ([@B55]). Moreover, FGFR1 has been shown to directly interact with neurotransmitter receptors (adenosine 2A receptor and 5-HT1A receptor), and modulate neurochemistry ([@B16]; [@B8]). Interestingly, the FGF system may be able to compensate for the brain-derived neurotrophic factor (BDNF) system in the mesolimbic system of BDNF knockdown mice ([@B7]). Briefly, FGF ligands interact with FGF membrane receptors on the surface of neurons and glial cells or with voltage-gated sodium channels intracellularly. In addition, FGF receptors have partners such as neural cell adhesion molecules (NCAM) and 5-HT1A receptor (a G-protein coupled receptor). These events trigger a host of signaling pathways mentioned before (AKT, MAPK, PLCγ), and regulate neurogenesis, neuroplasticity or influence signal transduction. Furthermore, they regulate ongoing behavior including stress response, anxiety, motivated and affective behavior or episode of depression ([@B82]).

FGFs in Other Mood Disorders
----------------------------

Besides depression, FGFs are associated with other mood disorders. The correlation between FGF2 and anxiety is most often elucidated. High-anxiety rats have lower levels of FGF2 mRNA in hippocampus compared with low-anxiety ones ([@B59]). The FGF2 knockdown in the hippocampus of rats by short-hairpin RNA silencing increases anxiety behavior ([@B14]). Similarly, the FGF2 knockout was reported to increase hypothalamic-pituitary-adrenal axis (HPA) activity and anxiety behavior in mice ([@B61]). Moreover, peripheral FGF2 administration both in early-life and in adulthood of rats significantly reduces anxiety behavior ([@B59]; [@B81]). And the anxiolytic effect of fluoxetine must be mediated by FGF2 through the study of FGF2 knockout mice ([@B65]). In addition, FGF8 and FGF21 can also affect anxiety behavior, and they exert their influence in opposite directions. FGF8-deficient mice display increased anxiety-like behavior, while FGF21 administration in rats induces anxiogenic behavior ([@B10]; [@B12]). As for bipolar disorder, serum levels of FGF2 are higher in patients with manic episode than those in healthy controls ([@B43]). FGF2 is related to bipolar disorder at the genetic level of humans ([@B89]). Similarly, FGFR2 is found to be associated with bipolar disorder through SNPs genotyping in humans ([@B86]).

Discussion
==========

Through reviewing existing studies, we found that the expression levels of some members of the FGF family were disordered in patients with depression, which indicates that a certain link exists between the FGF family and depression. But researches on the relation between FGF family and depression are not enough at present and the results of animal, postmortem and clinical studies have not been completely agreed.

Fibroblast growth factors and their roles in development, diseases, and therapies have been studied extensively. However, the study of FGFs in psychopathology, especially in depression, is an emerging field. To our best knowledge, it is the first review that focused on the neuromodulation effect of FGFs in depression. So far, there are limited studies showing the association between FGFs and depression, and the research methods are diverse and lack of homogeneity. Different experimental conditions, such as brain region, sample pH, and postmortem interval as we mentioned before, may lead to difference in the results of postmortem studies. Moreover, sample size, inclusion criteria, gender, therapeutic status of patients may play a role in the heterogeneity of results in clinical trials. In addition, previous studies only focused on the relations between FGF levels and depression, but seldom mentioned the deep connections between them and other depression-related disorders like anxiety. More attention should be paid on the signaling pathway and genetic variation of FGFs in depression, which may help to enrich the existing theories about the pathogenesis of depression.
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